Comparison · NCT00312208-sae
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events. Trial comparisons, record NCT00312208-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00312208-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.203 | 0.184 | 0.223 | wilson | |
| Risk in group 2 | 0.318 | 0.296 | 0.341 | wilson | |
| Risk difference, group 1 minus group 2 | -0.115 | -0.145 | -0.0855 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.637 | 0.565 | 0.718 | log | |
| Odds ratio, group 1 over group 2 | 0.545 | 0.464 | 0.639 | log | |
Number needed to treat, for one fewer participant with a serious adverse event on Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) than on Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 8.66 | 6.89 | 11.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles. | 331 | 1,634 | EG000 |
| Group 2 | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel. | 520 | 1,635 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Docetaxel in Breast Cancer
- NCT number
- NCT00312208
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Lead sponsor
- Sanofi
- Results first posted
- 2010-02-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00312208?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00312208-sae